Regenerative Medicine

GenCure’s formation was officially announced on August 11, 2011 by President and Chief Operating Officer Mary Beth Fisk. GenCure, a new arm of STBTC, will focus on a coalescence of providing cell and tissue services for regenerative medicine, including patient treatment and clinical research on a global basis.

“We see wonderful, new opportunities in regenerative medicine,” said Fisk. “This new focus with GenCure will help us position ourselves to take advantage of the solid reputation we’ve built through our work with the tissue and cellular therapy program and give us a strong launch in the regenerative medicine field.”

GenCure encompasses the bone marrow donor registration, tissue services, peripheral blood and cord blood cellular therapy programs. STBTC is pleased to continue its life saving mission and explore new opportunities in the future with regenerative medicine nationally and internationally.

GenCure will provide an opportunity to take advantage of new technologies and state-of-the-art processing and testing methods based on our existing foundation in tissue and cell work and move into this wonderful new field – providing growth opportunity and establishing STBTC as a major player in regenerative medicine.

“In addition to these services on a regional and national level, we have ongoing research collaborations with Scripps Research Institute, the National Disease Research Interchange (NDRI), Cytonet, University of Texas Health Science Center, University of Illinois and Lonza Walkersville, Inc.,” said Fisk. “And, we are already working with partners internationally and see promising potential particularly in Asia, Europe, and South America.”

GenCure services are accredited by the American Association of Blood Banks, American Association of Tissue Banks, the International Organization of Standardization, and where applicable, states requiring HCT state licensure and regulated by the Food and Drug Administration.

The three existing entities – Texas Cord Blood Bank, Marrow Donor Program and South and Central Texas and Tissue Services – will continue in their traditional life saving modes, while at the same time moving towards the next level of scientific advancements in the field of regenerative medicine.